PT - JOURNAL ARTICLE AU - Ulrich A Walker AU - Lesley Ann Saketkoo AU - Oliver Distler TI - Haematopoietic stem cell transplantation in systemic sclerosis AID - 10.1136/rmdopen-2017-000533 DP - 2018 Jun 01 TA - RMD Open PG - e000533 VI - 4 IP - 1 4099 - http://rmdopen.bmj.com/content/4/1/e000533.short 4100 - http://rmdopen.bmj.com/content/4/1/e000533.full SO - RMD Open2018 Jun 01; 4 AB - Three randomised controlled trials of haematopoietic stem cell transplantation (HSCT) in systemic sclerosis (SSc) demonstrated long-term survival benefits, induction of clinically meaningful, sustained improvement of forced vital capacity with improvements in skin thickening, vasculopathy and health-related quality of life, in contrast to a clinical decline in standard of care control groups. These benefits, however, must be weighed against the increased risk of transplant-related mortality. Further, with disease progression, severe extensive internal organ involvement and damage ensues, constituting an exclusion criterion for safety reasons, leaving a limited window whereby patients with SSc are eligible for HSCT. Although autologous HSCT offers the possibility of drug-free remission, relapse can occur, requiring re-initiation of disease modifying antirheumatic drugs. HSCT is also associated with secondary autoimmune diseases and gonadal failure. HSCT should be proposed for carefully selected patients with early rapidly progressive diffuse SSc whose clinical picture portends a poor prognosis for survival, but yet lacks advanced organ involvement.